Platinum complexes with binding affinity for the estrogen receptor.

Area of Science:

• Medicinal Chemistry
• Molecular Pharmacology
• Organic Synthesis

Background:

• Estrogen receptors (ERs) are crucial targets for hormone-dependent diseases.
• Platinum(II) complexes are investigated for their therapeutic potential.
• Developing novel ligands with specific receptor binding is essential.

Purpose of the Study:

• To synthesize novel (1,2-diaminoethane)dichloroplatinum(II) complexes.
• To evaluate the binding affinities of these complexes to the calf uterine estrogen receptor.
• To investigate the influence of different spacer groups on binding efficacy.

Main Methods:

• Synthesis of platinum(II) complexes incorporating dihydroxy-2-phenylindole moieties.
• Variable-length spacer groups (e.g., n-hexyl, p-xylene) were utilized.
• Relative Binding Affinity (RBA) assays were performed using calf uterine estrogen receptor.

Main Results:

• The synthesized platinum(II) complexes demonstrated binding to the estrogen receptor.
• The n-hexyl spacer (complex 16c) exhibited the highest RBA (6.5), followed by the p-xylene spacer (complex 17c) with an RBA of 4.4.
• These binding affinities were comparable to those of the parent diaminoethane ligands.

Conclusions:

• The incorporation of specific spacer groups significantly influences the estrogen receptor binding affinity of platinum(II) complexes.
• The n-hexyl and p-xylene spacers represent effective linkers for enhancing ER binding.
• These findings suggest potential for developing novel platinum-based therapeutics targeting estrogen receptors.